Feasibility Study of the Supply Chain for At-211 Radiopharmaceuticals in California
| Reference number | |
| Coordinator | Atley Solutions AB |
| Funding from Vinnova | SEK 999 964 |
| Project duration | October 2025 - September 2026 |
| Status | Ongoing |
| Venture | Deepened international collaborations |
| Call | Deepened collaboration with USA, UK and Singapore within Health and Life Science |
Purpose and goal
Atley Solutions, the Cyclotron and the Radiochemistry Facility (CRF) within the Canary Center for Early Detection at Stanford University and a leading global radiopharmaceutical company, will collaboratively establish and demonstrate a supply chain for astatine-211 (At-211) targeted radiopharmaceuticals in California. The project will enable non-clinical and clinical research on At-211 therapies and support the development of improved treatments for patients with high unmet medical needs.
Expected effects and result
Successful implementation will establish At-211 production in California, benefiting researchers at Stanford and patients in California and beyond. The global radiopharmaceutical company will gain access to a complete supply chain for the clinical translation of At-211 drugs. Atley will enter the Californian market, strengthening Sweden’s role in targeted radionuclide therapy and supporting future partnerships and funding.
Planned approach and implementation
Atley will perform technology development to adapt current technology to suit local supply chain requirements. Atley will subsequently install relevant technology at Stanford to enable on-site At-211 radiopharmaceutical manufacturing. The infrastructure will be utilized to produce a clinical dose of the global radiopharmaceutical company’s proprietary At-211 drug in a feasibility study at Stanford University.